Wolf James G. 4

Accession 0001290929-23-000005

CIK 0000316253other

View on SEC.gov Company Profile

Filed

Jan 18, 7:00 PM ET

Accepted

Jan 19, 2:37 PM ET

Size

67.1 KB

Accession

0001290929-23-000005

Insider Transaction Report

Form 4

Period: 2022-10-31

ENZO BIOCHEM INCENZ

Wolf James G.

10% Owner

Transactions

Conversion
Common Stock, $0.01 par value
2022-11-17$2.50/sh+300$750→ 3,535,300 total
Conversion
Common Stock, $0.01 par value
2022-12-15$2.50/sh+85,100$212,750→ 3,781,300 total
Conversion
Common Stock, $0.01 par value
2022-12-16$2.50/sh+33,700$84,250→ 3,815,000 total
Sale
Short Put Option (obligation to buy)
2022-11-01$0.80/sh+490$392→ 800 total
Exercise: $2.50From: 2022-11-01Exp: 2023-04-21→ Common Stock, $0.01 par value (49,000 underlying)
Purchase
Long Call Option (right to buy)
2022-11-01$0.65/sh+490$319→ 1,250 total
Exercise: $2.50From: 2022-11-01Exp: 2023-04-21→ Common Stock, $0.01 par value (49,000 underlying)
Sale
Short Put Option (obligation to buy)
2022-11-03$0.64/sh+200$128→ 1,250 total
Exercise: $2.50From: 2022-11-03Exp: 2023-04-21→ Common Stock, $0.01 par value (20,000 underlying)
Conversion
Short Put Option (obligation to buy)
2022-12-14−1,362→ 3,138 total
Exercise: $2.50From: 2022-11-01Exp: 2023-01-20→ Common Stock, $0.01 par value (136,200 underlying)
Sale
Long Call Option (right to buy)
2022-12-30$0.05/sh−6$0→ 3,244 total
Exercise: $2.50From: 2022-12-30Exp: 2023-01-20→ Common Stock, $0.01 par value (600 underlying)
Conversion
Common Stock, $0.01 par value
2022-11-21$2.50/sh+24,700$61,750→ 3,560,000 total
Conversion
Common Stock, $0.01 par value
2022-12-14$2.50/sh+136,200$340,500→ 3,696,200 total
Purchase
Common Stock, $0.01 par value
2022-11-01$2.15/sh+3,500$7,525→ 418,500 total(indirect: See Footnote)
Purchase
Long Call Option (right to buy)
2022-11-01$0.65/sh+10$7→ 760 total
Exercise: $2.50From: 2022-11-01Exp: 2023-04-21→ Common Stock, $0.01 par value (10,000 underlying)
Sale
Short Put Option (obligation to buy)
2022-11-03$0.62/sh+250$155→ 1,050 total
Exercise: $2.50From: 2022-11-03Exp: 2023-04-21→ Common Stock, $0.01 par value (25,000 underlying)
Purchase
Long Call Option (right to buy)
2022-11-03$0.44/sh+200$88→ 1,700 total
Exercise: $2.50From: 2022-11-03Exp: 2023-04-21→ Common Stock, $0.01 par value (20,000 underlying)
Sale
Short Put Option (obligation to buy)
2022-11-03$0.30/sh+9$3→ 248 total
Exercise: $2.50From: 2022-11-03Exp: 2022-11-18→ Common Stock, $0.01 par value (900 underlying)
Purchase
Common Stock, $0.01 par value
2022-11-01$2.14/sh+5,000$10,700→ 400,500 total(indirect: See Footnote)
Purchase
Common Stock, $0.01 par value
2022-10-31$2.15/sh+14,500$31,175→ 415,000 total(indirect: See Footnote)
Purchase
Long Call Option (right to buy)
2022-11-01$0.44/sh+500$220→ 3,250 total
Exercise: $2.50From: 2022-11-01Exp: 2023-01-20→ Common Stock, $0.01 par value (50,000 underlying)
Sale
Short Put Option (obligation to buy)
2022-11-01$0.69/sh+500$345→ 4,500 total
Exercise: $2.50From: 2022-11-01Exp: 2023-01-20→ Common Stock, $0.01 par value (50,000 underlying)
Sale
Short Put Option (obligation to buy)
2022-11-01$0.80/sh+10$8→ 310 total
Exercise: $2.50From: 2022-11-01Exp: 2023-04-21→ Common Stock, $0.01 par value (10,000 underlying)
Purchase
Long Call Option (right to buy)
2022-11-03$0.42/sh+250$105→ 1,050 total
Exercise: $2.50From: 2022-11-03Exp: 2023-04-21→ Common Stock, $0.01 par value (25,000 underlying)
Sale
Short Put Option (obligation to buy)
2022-11-03$0.60/sh+2$1→ 250 total
Exercise: $2.50From: 2022-11-03Exp: 2022-11-18→ Common Stock, $0.01 par value (200 underlying)
Conversion
Short Put Option (obligation to buy)
2022-11-21−247→ 0 total
Exercise: $2.50From: 2022-11-03Exp: 2022-11-18→ Common Stock, $0.01 par value (24,700 underlying)
Sale
Long Call Option (right to buy)
2022-12-05$0.20/sh−57$11→ 1,443 total
Exercise: $2.50From: 2022-12-05Exp: 2023-04-21→ Common Stock, $0.01 par value (5,700 underlying)
Conversion
Short Put Option (obligation to buy)
2022-12-15−851→ 2,287 total
Exercise: $2.50From: 2022-11-01Exp: 2023-01-20→ Common Stock, $0.01 par value (85,100 underlying)
Sale
Short Put Option (obligation to buy)
2022-12-15$1.25/sh+56$70→ 1,306 total
Exercise: $2.50From: 2022-12-15Exp: 2023-04-21→ Common Stock, $0.01 par value (5,600 underlying)
Conversion
Short Put Option (obligation to buy)
2022-11-17−3→ 247 total
Exercise: $2.50From: 2022-11-03Exp: 2022-11-18→ Common Stock, $0.01 par value (300 underlying)
Sale
Long Call Option (right to buy)
2022-12-05$0.25/sh−200$50→ 1,500 total
Exercise: $2.50From: 2022-12-05Exp: 2023-04-21→ Common Stock, $0.01 par value (20,000 underlying)
Sale
Long Call Option (right to buy)
2022-12-06$0.15/sh−443$66→ 1,000 total
Exercise: $2.50From: 2022-12-06Exp: 2023-04-21→ Common Stock, $0.01 par value (44,300 underlying)
Sale
Short Put Option (obligation to buy)
2022-12-15$1.29/sh+444$573→ 1,750 total
Exercise: $2.50From: 2022-12-15Exp: 2023-04-21→ Common Stock, $0.01 par value (44,400 underlying)
Conversion
Short Put Option (obligation to buy)
2022-12-16−337→ 1,413 total
Exercise: $2.50From: 2022-11-01Exp: 2023-04-21→ Common Stock, $0.01 par value (33,700 underlying)

Footnotes (4)

[F1]The counterparty to certain of the Reporting Person's outstanding short put options exercised such options and the Reporting Person was obliged to purchase these shares at an exercise price of $2.50 per share.
[F2]This transaction was completed in the name and for the benefit of the Reporting Person's sibling. The Reporting Person maintains a power of attorney granted by the Reporting Person's sibling with respect to these shares, including voting and dispositive power over the shares. The Reporting Person has no pecuniary interest in the shares and disclaims beneficial ownership of the securities held by his sibling. This report will not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
[F3]The transaction was completed in the name and for the benefit of one or more of the Reporting Person's adult children. The Reporting Person maintains power of attorney granted by each of his adult children with respect to these shares, including voting and dispositive power over the shares. The Reporting Person has no pecuniary interest in the shares and disclaims beneficial ownership of the securities held by his adult children. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act or 1934, as amended, or for any other purpose.
[F4]The 418,500 shares owned indirectly by the Reporting Person upon completion of this Transaction included 116,000 shares held in qualified retirement accounts in the name, and for the benefit, of the Reporting Person, 22,000 shares held in qualified retirement accounts in the name, and for the benefit, of the Reporting Person's spouse, 110,000 shares owned directly by the Reporting Person's sibling and 170,500 shares owned directly by adult children of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

ENZO BIOCHEM INC

CIK 0000316253

→

Entity typeother

Related Parties

filerCIK 0001419248

Filing Metadata

Form type: 4
Filed: Jan 18, 7:00 PM ET
Accepted: Jan 19, 2:37 PM ET
Size: 67.1 KB

View on SEC.gov